Please sign in to follow a disease.
Verruga peruana
MONDO:0971058A rare bacterial infectious disease characterized by development of endothelial cell-derived, blood-filled tumors on the surface of the skin during the chronic phase of infection with Bartonella bacilliformis. The lesions can persist for months to years and may cause pain and scarring due to ulceration. They are classified as miliary (multiple red papules of <3 mm in diameter), mular (blood-filled nodules), and diffuse (groups of subdermal nodules >5 mm in diameter). Eruptions may be accompanied by fever and malaise, lymphadenopathy, acute bone and joint pains, and headache. Fatality rates during this phase are low.
8 clinical trials for this condition and its sub-types.
Follow this condition to get notified about new trialsBroader categories
-
New antibiotic shows promise for newborns with dangerous infections
Disease control CompletedThis study looked at how the antibiotic cefiderocol works in hospitalized infants under 3 months old with suspected or confirmed gram-negative bacterial infections. Researchers measured drug levels in the blood and checked for side effects in 30 babies. The goal was to find the r…
Phase 2 • Sponsor: Shionogi • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New antibiotic shows promise for kids with tough infections
Disease control CompletedThis study tested the safety and how the body processes the antibiotic cefiderocol in hospitalized children aged 3 months to 18 years with serious bacterial infections. The goal was to see if the drug is safe and how it works in the body. 53 children participated, and the study i…
Phase 2 • Sponsor: Shionogi • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New antibiotic shows promise for kids with tough infections
Disease control CompletedThis study tested a new antibiotic called MK-7655A in 115 children from birth to 18 years old who had serious bacterial infections. The goal was to see if the drug is safe and works better than standard treatments. Children were randomly assigned to receive either the new drug or…
Phase 2/3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC